Wave life sciences highlights therapeutic potential for wve-006 for alpha-1 antitrypsin deficiency and progress bringing rna editing to the clinic during analyst and investor event

Wve-006 is the most advanced candidate for aatd designed to restore functional wild-type aat protein and reduce z-aat protein aggregation with potential for disease modification in both lung and liver phenotypes
WVE Ratings Summary
WVE Quant Ranking